Cite
MLA Citation
F D Richard Hobbs et al.. “1924. Outpatient Treatment With the SARS-CoV-2–Neutralizing Antibody Combination AZD7442 (Tixagevimab/Cilgavimab) for Preventing COVID-19 Hospitalizations in the Phase 3 TACKLE Trial.” Open forum infectious diseases, vol. 9, n.d., p. . http://access.bl.uk/ark:/81055/vdc_100174900630.0x000013